Hidoc News | News and Updates

Today's Updates

Baseline RV Dysfunction May predict Sotatercept response in PAH

Published Date: 05 Nov 2026

Baseline RV Dysfunction May predict Sotatercept response in PAH

FDA Grants Priority Review to Huntington Disease Gene Therapy BLA Marco Meglio

Published Date: 05 Nov 2026

The FDA accepted uniQure's biologics license application for ifezuntirgene inilparvovec and granted it Priority Review, setting a target action date of May 1, 2027.

On Beyond Seizures: Unmet Needs in Pediatric Epilepsy Clinics Susan Duberstein, MD

Published Date: 05 Nov 2026

Pediatric epilepsy care goes beyond seizures, addressing mental health, learning needs, coordinated referrals, equitable access, and smoother transition to adult services.

Alzheimer Agent Sabirnetug Misses Primary Endpoint, Acumen Halts Development Marco Meglio

Published Date: 05 Nov 2026

Sabirnetug failed to meet its primary endpoint in Acumen Pharmaceuticals' phase 2 ALTITUDE-AD trial for early Alzheimer disease, prompting the company to end development.

AL-S Pharma Details Planned Phase 3 Trial Design for AP-101 in ALS Marco Meglio

Published Date: 05 Nov 2026

AL-S Pharma outlined the design of AP101-03, a planned phase 3 trial of AP-101 in sporadic and SOD1-associated ALS, at the 2026 NEALS Annual Meeting.

Brezosiran Demonstrates Mutant Huntingtin Reduction in Phase 1b Huntington Disease Study Louie Pasculli

Published Date: 05 Nov 2026

Alnylam Pharmaceuticals reported initial Phase 1b findings showing brezosiran reduced cerebrospinal fluid mutant huntingtin levels by a mean of 60% to 64% at 3 months, with plans for a pivotal study in 2027.

NeuroVoices: Cindy Zadikoff, MD, MSc, on the FDA Approval of Tavapadon for Parkinson Disease Isabella Ciccone, MPH, Cindy Zadikoff, MD, MSc

Published Date: 05 Nov 2026

The executive medical director at AbbVie discussed the FDA approval of tavapadon, the first D1/D5 dopamine agonist for Parkinson disease, including the supporting TEMPO trial data and safety considerations.

Bioengineered Vessel for Dialysis Access Integrates With Patient Cells

Published Date: 05 Nov 2026

Bioengineered Vessel for Dialysis Access Integrates With Patient Cells

Bioengineered Vessel Adds 91 Catheter-Free Days for Women on Dialysis

Published Date: 05 Nov 2026

Bioengineered Vessel Adds 91 Catheter-Free Days for Women on Dialysis

Clinician FAQ: Using Remibrutinib (Rhapsido) for Symptomatic Dermographism

Published Date: 05 Nov 2026

Clinician FAQ: Using Remibrutinib (Rhapsido) for Symptomatic Dermographism

Today's Updates

Baseline RV Dysfunction May predict Sotatercept response in PAH

FDA Grants Priority Review to Huntington Disease Gene Therapy BLA Marco Meglio

On Beyond Seizures: Unmet Needs in Pediatric Epilepsy Clinics Susan Duberstein, MD

Alzheimer Agent Sabirnetug Misses Primary Endpoint, Acumen Halts Development Marco Meglio

AL-S Pharma Details Planned Phase 3 Trial Design for AP-101 in ALS Marco Meglio

Brezosiran Demonstrates Mutant Huntingtin Reduction in Phase 1b Huntington Disease Study Louie Pasculli

NeuroVoices: Cindy Zadikoff, MD, MSc, on the FDA Approval of Tavapadon for Parkinson Disease Isabella Ciccone, MPH, Cindy Zadikoff, MD, MSc

Bioengineered Vessel for Dialysis Access Integrates With Patient Cells

Bioengineered Vessel Adds 91 Catheter-Free Days for Women on Dialysis

Clinician FAQ: Using Remibrutinib (Rhapsido) for Symptomatic Dermographism

Latest News

Rare Tumor in a Rare Location in Patient With Constipation

ASTRO: American Society for Radiation Oncology

A Surgical First for Removal of an Appendiceal Neoplasm

What's Behind the Mysterious Chest Pain in Bladder Cancer Patient?

Cancer Deaths Fall, Cases Rise; Diabetes and Cancer Risk; Vitamin C for Cancer

Benign or Malignant? No Way to Tell Radiologically

FDA Advisors Recommend Galleri Multicancer Blood Test

FDA Approves New Option for Previously Treated Bile Duct Cancer

Optimizing Care Transitions and Referral Decision-Making Across the HNSCC Continuum

Here's Why Hematuria in a Young Patient Should Always Be Investigated

Liver Failure or Liver Mets?

Diagnosis of Mass Confined to the Kidney: Is It RCC or TCC?

BRAF Inhibition in Pediatric Ameloblastoma of the Jaw

Transforming Perioperative MIBC Care in Community Practice: Navigating Emerging Data, Guideline Changes, and Adverse Event Management Protocols

Doctors Remain Trusted Sources for Cancer Info in Post-Pandemic Era

Blood Cancer's First New Drug in 29 Years; AI for Mammography? Phase III Myeloma Win

Latest News

Rare Tumor in a Rare Location in Patient With Constipation

ASTRO: American Society for Radiation Oncology

A Surgical First for Removal of an Appendiceal Neoplasm

What's Behind the Mysterious Chest Pain in Bladder Cancer Patient?

Cancer Deaths Fall, Cases Rise; Diabetes and Cancer Risk; Vitamin C for Cancer

Benign or Malignant? No Way to Tell Radiologically

FDA Advisors Recommend Galleri Multicancer Blood Test

FDA Approves New Option for Previously Treated Bile Duct Cancer

Optimizing Care Transitions and Referral Decision-Making Across the HNSCC Continuum

Here's Why Hematuria in a Young Patient Should Always Be Investigated

Liver Failure or Liver Mets?

Diagnosis of Mass Confined to the Kidney: Is It RCC or TCC?

BRAF Inhibition in Pediatric Ameloblastoma of the Jaw

Transforming Perioperative MIBC Care in Community Practice: Navigating Emerging Data, Guideline Changes, and Adverse Event Management Protocols

Doctors Remain Trusted Sources for Cancer Info in Post-Pandemic Era

Blood Cancer's First New Drug in 29 Years; AI for Mammography? Phase III Myeloma Win

News All Time

Blood Cancer's First New Drug in 29 Years; AI for Mammography? Phase III Myeloma Win

More Evidence Ties Microplastics to Lung Cancer

Nationwide Epinephrine Recall; FBI's Fauci Probe; Bruce Campbell's Cancer

9/11's Latest Wave of Cancers, 25 Years On

Study Warns on Venetoclax in Double-Hit Lymphoma

Cancer Diagnosis, Then a Stroke; 9/11 Cancer Deaths; 'Grand Slam' Drug and Price

Local Consolidative Therapy After Dual Immunotherapy Fizzles in Metastatic NSCLC

Significant Survival Boost With Novel ADCs in Relapsed Small-Cell Lung Cancer

No Survival Bump in Metastatic NSCLC With Addition of ADC to Immunotherapy

Cancer Drug Shortages Continue With No Immediate Path Toward Relief

Brain MRI Surveillance Alone Helps Preserve Cognition in Small Cell Lung Cancer

Nurse Accused of Exorcism; Death After 8 Hours of Plastic Surgery; Top Cancer Months

Novel Drug Cuts Risk for Death by 44% in Squamous Lung Cancer Trial

Unprecedented PFS in HER2-Mutant Lung Cancer, but With a Touch of Controversy

Drug Combo's Response Rates Top 90% in Small Cell Lung Cancer Trial

ROS1-Targeting Lung Cancer Drug Yields 90% Response Rate

Recommended News For You

Let's Talk Breast Density; Cancer, Movies, and Music; Treatment-Induced Aging?

Bladder cancer link to explosive ordnance exposure among Army veteran bomb disposal officers

Early Esophageal Cancer pCR Rates Are Raised by Neoadjuvant PD-1 Blockade.

FINAL USPSTF RECOMMENDATIONS ON ANXIETY, DEPRESSION, AND SUIICIDAL RISK.

Belzutifan for Advanced Renal Cell Carcinoma is approved by the FDA.

Top Options Are Discovered Through Direct Comparison of 25 Migraine Drugs.

Which women need more than mammograms for breast cancer screening?

Recommended Articles For You

Apheresis vs. IVMP in Cancer Treatment: A Tale of Two Titans

Vaso Occlusive Crisis: Understanding the Painful Reality of Sickle Cell Disease

Expanding Oncology Frontiers: Rare Cancers, Breakthroughs, and Precision Medicine Advances

Smart Chemotherapy Chair Monitoring Infrastructure: Clinical Applications, Safety, and Future Directions

Whats more on Hidoc Dr.

Medical Updates

KOL Videos

Surveys

Events